You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福森藥業(01652.HK)擬1.53億元收購威海人生34%股權
格隆匯 12-31 21:49

格隆匯12月31日丨福森藥業(01652.HK)發佈公吿,於2020年12月31日,威海人生、苗其壯先生、威海浩洋及河南福森(公司的全資附屬公司)訂立投資框架協議,以由河南福森向威海浩洋收購威海人生(於公司重組後)的34%股權。

根據投資框架協議,河南福森同意訂立貸款協議,據此,河南福森將就第二次股權轉讓向威海浩洋借出本金額為人民幣9000萬元的貸款;及訂立買賣協議,據此,河南福森將有條件地收購而威海浩洋將有條件地出售威海人生的34%股權(於公司重組後),代價為人民幣1.53億元。

於買賣協議完成後,威海人生將由威海浩洋、河南福森、苗先生及高級管理層分別擁有約35.9%、34%、15.8%及14.3%權益。

威海人生於2014年成立,主要於中國從事中成藥(包括但不限於兒科藥物、骨科藥物及皮膚科藥物)的生產、銷售及研發。董事會認為,投資框架協議為集團提供良機,可利用威海人生於中國銷售及生產中成藥的經驗及專業知識,擴大集團的現有產品組合。

董事認為,集團於中國中成藥市場的市場份額可透過向威海人生投資而進一步增加,且集團可分散其收入來源。因此,董事認為,訂立投資框架協議可讓集團把握未來機遇及提升股東回報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account